Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 127Kidney Neoplasms 39Neoplasms 37Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 27Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Stomach Neoplasms 8Neuroendocrine Tumors 8Carcinoma 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Adenoma, Islet Cell 6Uveal Melanoma 5

Interventions

tremelimumab 1temsirolimus 1durvalumab 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Rare Tumours × Sunitinib × Clear all
NCT01396408 2026-03-27

A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours

Canadian Cancer Trials Group

Phase 2 Active not recruiting
137 enrolled

Advanced Rare Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡